Hematolo-Oncology Daily Report: 01/23/2024
Mantle Cell Lymphoma
A multicenter phase 1b/2 trial investigated the effect of venetoclax, lenalidomide, and rituximab (venetoclax-R2) in 59 patients with relapsed/refractory mantle cell lymphoma and found an overall response rate of 63%, median progression-free survival of 21 months, and median overall survival of 31 months (1). This trial was registered at www.ClinicalTrials.gov as #NCT03505944.
Reference
Jerkeman M, Kolstad A, Hutchings M, Pasanen A, Meriranta L, Niemann CU, Kragh Jørgensen RR, El-Galaly TC, Riise J, Leppä S, Christensen JH, Sonnevi K, Pedersen LB, Wader KF, Glimelius I. MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial. Blood Adv. 2024 Jan 23;8(2):407-415. doi: 10.1182/bloodadvances.2023011920. PMID: 38113470.
Mantle Cell Lymphoma
A Phase 1 study investigated the safety and tolerability of pelabresib in 44 patients with acute leukemia, high-risk myelodysplastic (MDS) syndrome, or MDS/myeloproliferative neoplasms and found that the maximum tolerated dose was 225 mg tablet QD (1). Stable disease was observed in 25.8% of acute myeloid leukemia (AML) patients and 38.5% of high-risk MDS patients. Partial remission was seen in one patient with chronic myelomonocytic leukemia (CMML) and peripheral hematologic response in one AML patient and one CMML patient. The study was registered under NCT02158858.
Reference
Stein EM, Fathi AT, Harb WA, Colak G, Fusco A, Mangan JK. Results from phase 1 of the MANIFEST clinical trial to evaluate the safety and tolerability of pelabresib in patients with myeloid malignancies. Leuk Lymphoma. 2024 Jan 23:1-8. doi: 10.1080/10428194.2023.2300710. Epub ahead of print. PMID: 38259250.